Funder: Breakthrough T1D
Due Dates (Anticipated): August 2025 (Webinar) | October 2025 (LOI) | January 2026 (Full proposal)
Funding Amounts: Up to $1.5M/year for up to 4 years (higher budgets/timelines require prior approval)
Summary: Supports clinical trials of small molecules, biologics, or combination therapies aimed at delaying, halting, or reversing type 1 diabetes progression in stage 3 patients.
Key Information: LOI required; industry and international applicants eligible; drug supply must be secured by applicant.